Psoriasis – Geographic Focus: China – Psoriasis – China In-Depth (China)

Non-TNF biologics (e.g., IL-17 inhibitors) are gaining momentum in China in the treatment of psoriasis, particularly moderate to severe disease. We expect that the growing psoriasis armamentarium and the entry of biosimilars will make treatment decisions increasingly complex, especially in the absence of clear differentiation between novel drugs and between drugs from the same class. Despite being listed in the NRDL, biologics still cost more than traditional treatment options, including topicals and conventional systemics (e.g., methotrexate, acitretin). Thus, although improving rapidly, China’s market access and reimbursement environment still limits the use of these drugs to later lines (i.e., patients who do not respond to traditional treatments). In this report, we explore the impact of unmet needs, pricing, coverage, and regulatory reforms in China on the success of current and future players in this highly lucrative market.

Questions answered

  • How large is China’s drug-treatable psoriasis population, and how will drug-treatment rates change during the forecast period?
  • Which are the most commercially relevant drugs in China’s psoriasis market, and why? What are interviewed experts’ insights into current treatments?
  • What are the key unmet needs in the management of psoriasis?
  • What are the key market access considerations, and how are they likely to impact the uptake of emerging drugs in this market?
  • How will this market evolve over the next 10 years?

Product description

China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

launch Related Market Assessment Reports